Thermo Fisher Scientific Expands Neurodegeneration Research Capabilities With Launch Of Olink® Target 48 Neurodegeneration Panel

Thermo Fisher Scientific Inc., nan world leader successful serving science, coming announced nan motorboat of the Olink® Target 48 Neurodegeneration panel, a high-performance, targeted proteomics immunoassay sheet developed to accelerate discoveries successful neurodegenerative illness research. With diseases specified arsenic Alzheimer’s, aggregate sclerosis and Parkinson’s connected nan emergence and objective pipelines eager for translational biomarkers, researchers look a pressing request for scalable, reproducible and disease-relevant macromolecule measurement. This sheet delivers simultaneous measurement of 41 cardinal and emerging proteins for neurodegeneration investigation pinch absolute quantification and optimized for plasma measurement from arsenic small arsenic 1 µL of sample.

The Target 48 Neurodegeneration sheet is nan latest summation to Olink’s increasing portfolio of multiplex illness panels pinch absolute quantification readouts. Alongside nan Olink® Target 48 Cytokine, Olink® Target 48 Immune Surveillance, and nan semi-custom Olink® Flex platform, this solution helps create a powerful ecosystem for proteomics research. When combined, these panels let researchers to seamlessly analyse a larger room of macromolecule biomarkers that tin thief supply broad insights into neurodegeneration and inflammation successful nan body.

An early entree user, Charlotte Teunissen, professor successful neurochemistry astatine nan Department of Laboratory Medicine astatine Amsterdam University Medical Center, shared, “The Target 48 Neurodegeneration sheet is simply a captious instrumentality that enables nan discovery and quantification of cardinal and emerging neurodegenerative illness biomarkers from plasma and cerebrospinal fluid samples. By generating quantitative data, it ensures reproducible results crossed and wrong longitudinal studies, moving a measurement guardant towards objective utilization.”

Neurological diseases are complex, multifactorial and urgently successful request of translational insights particularly pinch non-invasive proteomic biomarkers for longitudinal monitoring,

The panel, designed successful adjacent collaboration pinch starring objective researchers, offers absolute quantification of multiplex cardinal biomarkers to show illness progression and therapeutic responses to powerfulness precision medicine."

Yan Zhang, President of nan Proteomic Sciences business, Thermo Fisher Scientific

Key benefits of the Olink® Target 48 Neurodegeneration include:

• Targeted depth: 41 macromolecule biomarkers selected for relevance crossed Alzheimer's disease, aggregate sclerosis, amyotrophic lateral sclerosis, Parkinson’s illness and different neurodegenerative disorders.
• Absolute quantification: Ability to quantify cardinal and emerging biomarkers for neurodegeneration investigation simultaneously successful 1 panel.
• Minimal sample input: Enables high-throughput studies pinch precious aliases biobank samples.
• Scalability and standardization: Compatible pinch Thermo Fisher’s world web of Olink-equipped labs for reproducibility crossed sites, captious for multi-center tests and ample consortia.
• Proven solution: Uses Olink’s gold-standard Proximity Extension Assay (PEA) technology.

The caller sheet reinforces Thermo Fisher’s committedness to advancing precision medicine and neurology research, joining nan company’s broader suite of devices spanning wide spectrometry, cryo-electron microscopy, and multiplex immunoassays. It builds connected caller initiatives specified arsenic nan UK Biobank proteomics program, nan Geisinger Health Study pinch nan Regeneron Genetics Center and cross-platform collaborations pinch starring biopharma companies.

The Olink® Target 48 Neurodegeneration has been developed pinch nan purpose of reducing import barriers specified arsenic agelong lead-times for importing into geographies pinch humor aliases plasma-derived import licenses. The Olink® Target 48 Neurodegeneration sheet is afloat compatible pinch nan Olink® Signature Q100 benchtop system, providing a simplified workflow, minimal instrumentality attraction and streamlined value control, enabling laboratories to accelerate their biomarker research.